Gainesville, FLORIDA2 Active Studies

Prader-Willi Syndrome Clinical Trials in Gainesville, FLORIDA

Find 2 actively recruiting prader-willi syndrome clinical trials in Gainesville, FLORIDA. Connect with local research sites and explore new treatment options.

2
Active Trials
1
Sponsors
180
Enrolling

Recruiting Prader-Willi Syndrome Studies in Gainesville

About Prader-Willi Syndrome Clinical Trials in Gainesville

Prader-Willi syndrome is a rare genetic disorder caused by loss of gene function on chromosome 15, leading to constant hunger, obesity, intellectual disability, and short stature. It is the most common genetic cause of life-threatening obesity. Management includes growth hormone therapy and strict dietary supervision.

There are currently 2 prader-willi syndrome clinical trials recruiting participants in Gainesville, FLORIDA. These studies are seeking a combined 180 participants. Research is being sponsored by Aardvark Therapeutics, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prader-Willi Syndrome Clinical Trials in Gainesville — FAQ

Are there prader-willi syndrome clinical trials in Gainesville?

Yes, there are 2 prader-willi syndrome clinical trials currently recruiting in Gainesville, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Gainesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Gainesville research site will contact you about next steps.

Are clinical trials in Gainesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Gainesville studies also compensate for your time and travel.

What prader-willi syndrome treatments are being tested?

The 2 active trials in Gainesville are testing new therapies including novel drugs, biologics, and treatment approaches for prader-willi syndrome.

Data updated March 2, 2026 from ClinicalTrials.gov